Published in TB and Outbreaks Week, August 19th, 2003
"Even on day 70, mixed chimerism remained together with a quite high viral load," noted M. Hagihara and colleagues at Tokai University. "On days 76 and 90, donor lymphocytes were infused after short-term culture with OKT3 plus recombinant IL-2."
"At 8 days after the last dose, all hematopoietic cells were shown to be donor-type...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.